Comparing IDEXX Laboratories (IDXX) and Heska Corporation (NASDAQ:HSKA)

IDEXX Laboratories (NASDAQ: IDXX) and Heska Corporation (NASDAQ:HSKA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitabiliy, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

89.0% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 81.8% of Heska Corporation shares are owned by institutional investors. 2.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 14.7% of Heska Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares IDEXX Laboratories and Heska Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IDEXX Laboratories 13.47% -706.91% 15.74%
Heska Corporation 10.45% 15.20% 10.96%

Volatility & Risk

IDEXX Laboratories has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Heska Corporation has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Valuation and Earnings

This table compares IDEXX Laboratories and Heska Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
IDEXX Laboratories $1.82 billion 8.04 $449.79 million $2.71 61.27
Heska Corporation $133.32 million 5.47 $21.99 million $1.87 54.83

IDEXX Laboratories has higher revenue and earnings than Heska Corporation. Heska Corporation is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for IDEXX Laboratories and Heska Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories 2 2 2 0 2.00
Heska Corporation 0 4 2 0 2.33

IDEXX Laboratories currently has a consensus price target of $161.00, suggesting a potential downside of 3.03%. Heska Corporation has a consensus price target of $94.13, suggesting a potential downside of 8.19%. Given IDEXX Laboratories’ higher probable upside, equities analysts plainly believe IDEXX Laboratories is more favorable than Heska Corporation.

Summary

IDEXX Laboratories beats Heska Corporation on 9 of the 13 factors compared between the two stocks.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Heska Corporation Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products. Its OVP segment includes private label vaccine and pharmaceutical production for cattle but also for other species, including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels. It focuses on supporting veterinarians in canine and feline healthcare space. It offers a line of veterinary blood testing and other instruments. It manufactures biological and pharmaceutical products for other animal health companies.

What are top analysts saying about IDEXX Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IDEXX Laboratories Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit